10.25Open10.25Pre Close0 Volume1 Open Interest2.50Strike Price0.00Turnover688.95%IV-44.69%PremiumOct 18, 2024Expiry Date20.55Intrinsic Value100Multiplier19DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9861Delta0.0010Gamma1.10Leverage Ratio-0.0339Theta0.0010Rho1.09Eff Leverage0.0019Vega
Nurix Therapeutics Stock Discussion
as this guy 👇
$Taysha Gene Therapies (TSHA.US)$ 21% FY 2023 results
$TFF Pharmaceuticals (TFFP.US)$ 14% Clinical programs update
$Jaguar Health (JAGX.US)$ 14% Crofelemer commercialization
$Acelyrin (SLRN.US)$ 4% Ph1/2 positive data
$Delcath Systems (DCTH.US)$ 3% Closes $7M private placement
$Sellas Life Sciences (SLS.US)$ 0% Closes $20M offering & private placement
$Immunic (IMUX.US)$ 1% Patent notice of allowance
$Nurix Therapeutics (NRIX.US)$ 0...
Nurix said patients currently enrolled in the trial who are deriving clinical benefit are allowed to continue receiving the current drug product. The screening and enrollment of new patients has been paused.
The company sai...
No comment yet